Trastuzumab was found to achieve a slight reduction in recurrence for women with HER2-positive ductal carcinoma in situ, stated clinical trial results.
from Medindia Health News https://ift.tt/2yM40j0
Sunday, 31 May 2020
Antibody Therapy Achieves Slight Reduction in Recurrence for Women With HER2-positive DCIS, Says Study
Trastuzumab was found to achieve a slight reduction in recurrence for women with HER2-positive ductal carcinoma in situ, stated clinical trial results.
from Medindia Health News https://ift.tt/2yM40j0
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment